Compare Vanguard Dividend Appreciation Index Fund ETF (VIG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Dividend Appreciation Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Dividend Appreciation Index Fund ETF trades at $238.99 (market cap $132.40B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 65.5× GeneDx Holdings Corp's market cap, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Dividend Appreciation Index Fund ETF for 134 Days and GeneDx Holdings Corp for 19 Days on average.
| VIG | WGS | |
|---|---|---|
Market Cap | $132.40B | $2.02B |
Volume | 1,287,188 | 734,640 |
52-Week High | $246.61 | $167.51 |
52-Week Low | $210.70 | $34.51 |
Typical Hold Time | 134 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VIG trades at $239.00, up 0.85% with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights its role in retirement portfolios and a 7.5% quarterly dividend increase, though year-to-date growth remains modest at 3.3%.
Outlook remains positive given VIG's quality focus and historical 10% annual returns, but risks include slow dividend growth and exclusion of high-yield stocks. The ETF suits investors seeking steady income with growth potential, though competition from SCHD and market volatility pose challenges to outperformance.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
